Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijng, China.
Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijng, China.
Eye (Lond). 2020 Aug;34(8):1459-1464. doi: 10.1038/s41433-020-0827-y. Epub 2020 Feb 24.
To evaluate intravitreal conbercept injection for treatment of macular oedema secondary to central retinal vein occlusion (CRVO) in Chinese patients during 1-year follow-up in the real-world setting.
Twenty-seven eyes of 27 patients with macular oedema associated with CRVO were retrospectively reviewed. The eyes received monthly intravitreal conbercept injection (0.5 mg in 50 µl) for 3 months. From then on, the patients were followed up every month and received injection pro re nata (PRN) up to 12 months. The primary outcome measurements included changes of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 3 and month 12. Other outcome measurements included proportion of patients gaining ≥15 letters in BCVA at month 3 and 12, the mean number of injections and safety concerns.
The mean BCVA gain from baseline was 12.7 ± 7.6 letters at month 3 and 14.8 ± 9.6 letters at month 12. The mean CRT reduction from baseline was 374.5 ± 280.7 μm at month 3 and 428.2 ± 241.3 μm at month 12. The proportion of patients who gained ≥15 letters in BCVA was 45.1% at month 3 and 52.9% at month 12. The mean number of injections was 7.6 ± 1.5. No severe local and systemic complications occurred following injection.
Intravitreal conbercept injection by three monthly loading doses followed by PRN treatment regimen was safe and efficacious for patients with macular oedema secondary to CRVO through 1-year follow-up.
评估康柏西普玻璃体腔内注射治疗中国患者视网膜中央静脉阻塞（CRVO）相关黄斑水肿的 1 年疗效。
回顾性分析 27 例（27 只眼）CRVO 相关黄斑水肿患者，每月玻璃体腔内注射康柏西普（50μl 中 0.5mg），连续 3 个月为负荷剂量，之后根据病情行玻璃体腔内注射治疗（PRN），随访 12 个月。主要观察指标包括治疗前、治疗后 3 个月及 12 个月最佳矫正视力（BCVA）和中心视网膜厚度（CRT）的变化。次要观察指标包括治疗后 3 个月及 12 个月 BCVA 提高≥15 个字母的患者比例、平均注射次数及安全性。
治疗后 3 个月和 12 个月 BCVA 平均分别提高 12.7±7.6 个和 14.8±9.6 个字母，CRT 平均分别降低 374.5±280.7μm 和 428.2±241.3μm。治疗后 3 个月和 12 个月 BCVA 提高≥15 个字母的患者比例分别为 45.1%和 52.9%。平均注射次数为 7.6±1.5 次。治疗过程中未见严重局部及全身不良反应。
玻璃体腔内注射康柏西普治疗方案为每月 3 次负荷剂量，之后根据病情行 PRN 治疗，治疗 CRVO 相关黄斑水肿安全有效，随访 1 年疗效持久。
